We have a suspicion that you are an automated web bot software, not a real user. To keep our site fast for other users, we have slowed down this page. The slowdown will gradually disappear. If you think this is a mistake, please contact us at genome-www@soe.ucsc.edu. Also note that all data for hgGeneGraph can be obtained through our public MySQL server and all our software source code is available and can be installed locally onto your own computer. If you are unsure how to use these resources, do not hesitate to contact us.
UCSC Genome Browser Gene Interaction Graph
Gene interactions and pathways from curated databases and text-mining
IDrugs 2010, PMID: 20506053

American association for cancer research - 101st annual meeting - investigating new therapeutic candidates: part 2.

Mason, Vicki L

The 101st Annual Meeting of the American Association of Cancer Research, held in Washington, DC, included topics covering new therapeutic developments in the field of cancer research. This conference report highlights selected presentations on preclinical data on the novel pan-PI3K pyrimidine-derived inhibitor BKM-120 (Novartis AG), the dual inhibition of mTOR/PI3K in NSCLC by PF-4691502 (Pfizer Inc), the small-molecule PDK-1 inhibitors PF-05177624 and PF-05197281 (both Pfizer) and the ability of RO-5323441 (F Hoffmann-La Roche Ltd/ThromboGenics NV/BioInvent International AB) to block tumor growth in vivo. Phase I clinical trial results for VB-111 (VBL Therapeutics) are also presented.

Diseases/Pathways annotated by Medline MESH: Neoplasms
Document information provided by NCBI PubMed

Text Mining Data

mTOR/PI3K ⊣ PDK-1: " This conference report highlights selected presentations on preclinical data on the novel pan-PI3K pyrimidine derived inhibitor BKM-120 ( Novartis AG ), the dual inhibition of mTOR/PI3K in NSCLC by PF-4691502 ( Pfizer Inc ), the small-molecule PDK-1 inhibitors PF-05177624 and PF-05197281 ( both Pfizer ) and the ability of RO-5323441 ( F Hoffmann-La Roche Ltd/ThromboGenics NV/BioInvent International AB ) to block tumor growth in vivo "

mTOR/PI3K ⊣ pan-PI3K: " This conference report highlights selected presentations on preclinical data on the novel pan-PI3K pyrimidine derived inhibitor BKM-120 ( Novartis AG ), the dual inhibition of mTOR/PI3K in NSCLC by PF-4691502 ( Pfizer Inc ), the small-molecule PDK-1 inhibitors PF-05177624 and PF-05197281 ( both Pfizer ) and the ability of RO-5323441 ( F Hoffmann-La Roche Ltd/ThromboGenics NV/BioInvent International AB ) to block tumor growth in vivo "

mTOR/PI3K ⊣ PDK-1: " This conference report highlights selected presentations on preclinical data on the novel pan-PI3K pyrimidine derived inhibitor BKM-120 ( Novartis AG ), the dual inhibition of mTOR/PI3K in NSCLC by PF-4691502 ( Pfizer Inc ), the small-molecule PDK-1 inhibitors PF-05177624 and PF-05197281 ( both Pfizer ) and the ability of RO-5323441 ( F Hoffmann-La Roche Ltd/ThromboGenics NV/BioInvent International AB ) to block tumor growth in vivo "

mTOR/PI3K ⊣ pan-PI3K: " This conference report highlights selected presentations on preclinical data on the novel pan-PI3K pyrimidine derived inhibitor BKM-120 ( Novartis AG ), the dual inhibition of mTOR/PI3K in NSCLC by PF-4691502 ( Pfizer Inc ), the small-molecule PDK-1 inhibitors PF-05177624 and PF-05197281 ( both Pfizer ) and the ability of RO-5323441 ( F Hoffmann-La Roche Ltd/ThromboGenics NV/BioInvent International AB ) to block tumor growth in vivo "

mTOR/PI3K ⊣ PDK-1: " This conference report highlights selected presentations on preclinical data on the novel pan-PI3K pyrimidine derived inhibitor BKM-120 ( Novartis AG ), the dual inhibition of mTOR/PI3K in NSCLC by PF-4691502 ( Pfizer Inc ), the small-molecule PDK-1 inhibitors PF-05177624 and PF-05197281 ( both Pfizer ) and the ability of RO-5323441 ( F Hoffmann-La Roche Ltd/ThromboGenics NV/BioInvent International AB ) to block tumor growth in vivo "

Manually curated Databases

No curated data.